Gilead Sciences (GILD) 주식 개요
바이오 제약 회사인 길리어드 사이언스는 미국, 유럽 및 전 세계의 미충족 의료 수요 분야에서 의약품을 발견, 개발 및 상업화하는 기업입니다. 자세히 보기
GILD Community Fair Values
Create NarrativeSee what 229 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$128.38
FV
3.6% 저평가 내재 할인율5.00%
Revenue growth p.a.
103
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Gilead Sciences, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$123.76 |
| 52주 최고가 | US$157.29 |
| 52주 최저가 | US$104.46 |
| 베타 | 0.33 |
| 1개월 변동 | -7.89% |
| 3개월 변동 | -9.89% |
| 1년 변동 | 14.06% |
| 3년 변동 | 59.75% |
| 5년 변동 | 82.32% |
| IPO 이후 변동 | 19,457.15% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Jun 12
GILD: Diversified Oncology And HIV Pipeline Will Support Future Earnings
Analyst price targets for Gilead Sciences have been refined to $180.00, with updated assumptions reflecting slightly lower revenue growth, a modestly higher profit margin, a small reduction in the discount rate, and a marginally lower future P/E, as analysts balance enthusiasm for assets like Trodelvy, Yeztugo, lenacapavir, and the Tubulis platform against more cautious long term expectations. Analyst Commentary Recent Street research shows a mix of enthusiasm and caution around Gilead, with bullish analysts highlighting specific growth drivers and valuation support while others keep a more measured stance on key oncology and I&I assets.Seeking Alpha • May 31
Gilead: 'Hold' On Biktarvy Sales Growth And MM Drug Development Program
Summary Gilead Sciences is maintained at 'Hold' as the HIV franchise drives growth, but the oncology pipeline requires further progress. BIKTARVY sales rose 7% to $3.4B in Q1 2026; the HIV portfolio might be expanded by the pending BIC/LEN combo with the August 2026 PDUFA. TRODELVY and anito-cel offer expansion catalysts, with key FDA decisions and trial readouts in 2H 2026 and late 2026. VEKLURY remains a drag; oncology pipeline growth and execution on new launches are critical to justify a rating upgrade. Read the full article on Seeking Alpha
내러티브 업데이트 • May 28
GILD: HIV And Oncology Pipeline Expansion Will Drive Long Term Upside
Gilead Sciences' updated analyst price target edges up to $157.83 from $157.43, with analysts pointing to slightly higher modeled revenue growth, a modestly higher assumed future P/E of about 22.4x, and the growing contribution they see from assets like Trodelvy, Yeztugo and the Tubulis platform, even as views on long term oncology and I&I potential remain restrained. Analyst Commentary Analysts are split between those leaning into Gilead's newer growth drivers and those keeping a closer eye on execution risks and valuation.
새로운 내러티브 • May 19
Attractive medium-term compounder with catalyst-rich profile, but with short-term volatility tied to investment phase
Below is a professional investment memo (buy‑side style, in English) on Gilead Sciences (GILD) based primarily on the 2025 Impact Report (pipeline + strategy + data extraction) and complemented with verified investor website + latest news analysis. Investment Memo – Gilead Sciences (NASDAQ: GILD) 1.
내러티브 업데이트 • May 01
GILD: Future Returns Will Hinge On Executing Oncology And ADC Acquisitions
Analysts have raised the Gilead Sciences fair value estimate by about $2 to $128.42 per share, supported by refreshed models that reflect updated revenue growth, profitability, and future P/E assumptions following a wave of higher Street price targets. Analyst Commentary Street research on Gilead has tilted constructive in recent weeks, with several firms lifting price targets and at least one new Buy rating added.내러티브 업데이트 • Apr 17
GILD: Oncology Deals And HIV Franchise Will Support Future Earnings
Analysts have raised the price target for Gilead Sciences to $180, citing recent upward revisions across Wall Street that reflect updated views on revenue growth, profitability and oncology deal activity. The core fair value estimate in this framework also remains at $180.내러티브 업데이트 • Apr 03
GILD: HIV And PrEP Franchise Will Support Future Earnings And Margin Strength
Analysts have lifted the fair value estimate for Gilead Sciences to $180 from $159, citing higher modeled revenue growth, a slightly lower discount rate, and support from a wave of recent price target raises and positive initiation commentary on the company’s positioning and operating margins. Analyst Commentary Street research around Gilead Sciences has been active, with several bullish analysts updating their views and price targets in recent weeks.내러티브 업데이트 • Mar 20
GILD: HIV Franchise And Oncology Expansion Will Shape Bullish Long Term Outlook
The analyst fair value estimate for Gilead Sciences has moved from $132.57 to $157.43, with analysts pointing to stronger modeled revenue growth, slightly higher long term profit margins, and a higher future P/E multiple supported by recent price target hikes and positive views on the company's positioning in large cap biotech. Analyst Commentary Recent Street research on Gilead Sciences reflects a mix of optimism around growth drivers and caution around valuation and competitive risks.내러티브 업데이트 • Mar 05
GILD: Rich HIV Outlook Will Depend On Delivering High-Risk Oncology Acquisitions
Analysts have lifted their Gilead Sciences fair value estimate from $122.64 to $126.09 as they update models to reflect revised revenue growth and profit margin assumptions, along with a slightly higher discount rate and a modestly lower future P/E multiple, following a wave of higher Street price targets in recent weeks. Analyst Commentary Recent Street research around Gilead Sciences shows a mix of optimism and restraint.내러티브 업데이트 • Feb 19
GILD: Elevated Future Expectations Will Hinge On Execution In Oncology
Gilead Sciences' updated analyst price target has moved sharply higher to $122.64 from $91.83, as analysts broadly lift their targets into the $140 to $170 range, citing steadier HIV franchise expectations, contributions from recent launches, and adjusted assumptions for expenses and oncology assets. Analyst Commentary Recent Street research shows a clear tilt toward higher valuation frameworks for Gilead Sciences, with several firms taking their targets into a broad US$140 to US$170 range.내러티브 업데이트 • Feb 05
GILD: Extended HIV And PrEP Strength Will Support Steady Long-Term Earnings Power
Narrative Update: Gilead Sciences Analyst Price Target Shift Analysts have lifted their price targets on Gilead Sciences by as much as US$20, pointing to updated HIV franchise expectations, revised oncology and PrEP assumptions, and refreshed valuation approaches, even as some models incorporate higher IPR&D expenses and adjusted sales forecasts. Analyst Commentary Recent Street research around Gilead centers on two big themes in the models: the durability of the HIV franchise and the ramp in newer areas like PrEP and oncology, with several bullish analysts lifting price targets and reaffirming positive ratings.내러티브 업데이트 • Jan 22
GILD: Extended HIV Franchise Strength Will Support Stronger Long-Term Earnings Power
Analysts have nudged their fair value estimate for Gilead Sciences up to $159 from $153, citing refreshed models that reflect updated HIV franchise expectations, oncology pipeline inputs, and evolving competitive readthroughs from peers in hepatitis and cell therapy. Analyst Commentary Recent Street research around Gilead Sciences has leaned constructive, with several bullish analysts refining their models and resetting price targets while pointing to HIV, oncology, and select liver and autoimmune assets as the key drivers they are watching.내러티브 업데이트 • Jan 07
GILD: HIV PrEP Strength And Oncology Mixed Results Will Shape Outlook
Analysts have nudged their price targets on Gilead Sciences higher, generally toward the US$140 to US$145 range. They cite expectations for stronger HIV PrEP contributions from Yeztugo, a healthier outlook for the broader HIV portfolio including Biktarvy, and ongoing support from oncology and newer launches such as Livdelzi.내러티브 업데이트 • Dec 20
GILD: Extended HIV Exclusivity Will Support Stronger Long-Term Earnings Power
Analysts have raised their fair value estimate for Gilead Sciences to $153 from $140, citing extended Biktarvy exclusivity, a stronger long term HIV growth outlook supported by Yeztugo and PrEP, and increasing conviction in oncology and broader large cap biopharma innovation potential. Analyst Commentary Bullish analysts continue to highlight Gilead as a core large cap biopharma holding, pointing to a healthier long term growth profile in HIV and a strengthening contribution from oncology.내러티브 업데이트 • Dec 06
GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead
Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.내러티브 업데이트 • Nov 22
GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures
Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.내러티브 업데이트 • Nov 08
GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead
Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.내러티브 업데이트 • Oct 25
Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies
Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.내러티브 업데이트 • Oct 10
Global Healthcare Trends Will Expand Access To Advanced Therapies
Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.내러티브 업데이트 • Sep 04
Global Healthcare Trends Will Expand Access To Advanced Therapies
Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.분석 기사 • Jul 27
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...주주 수익률
| GILD | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -1.5% | 1.3% | 1.4% |
| 1Y | 14.1% | 31.4% | 25.7% |
수익률 대 산업: GILD은 지난 1년 동안 31.4%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: GILD은 지난 1년 동안 25.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| GILD volatility | |
|---|---|
| GILD Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: GILD는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: GILD의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
바이오 제약 회사인 길리어드 사이언스는 미국, 유럽 및 전 세계의 미충족 의료 수요 분야에서 의약품을 발견, 개발 및 상업화하는 회사입니다. 이 회사는 HIV-1 감염 환자의 치료를 위해 빅타비, 데스코비, 젠보야, 오데프시, 순렌카, 심투자, 예츠투고 등을 공급하고 있습니다. 또한 만성 C형 간염 바이러스, 원발성 담즙성 담관염, 만성 B형 간염 바이러스 치료를 위한 에클루사, 리브델지, 베믈리디와 성인 환자 치료를 위한 T세포 치료제 테카투스, 정맥주사용 주사제 트로델비, 성인 환자 치료를 위한 CAR T세포 치료제인 정맥주사용 현탁액 예스카르타를 공급하고 있습니다.
Gilead Sciences, Inc. 기초 지표 요약
| GILD 기초 통계 | |
|---|---|
| 시가총액 | US$153.66b |
| 순이익 (TTM) | US$9.22b |
| 매출 (TTM) | US$29.74b |
16.7x
주가수익비율(P/E)5.2x
주가매출비율(P/S)GILD는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| GILD 손익계산서 (TTM) | |
|---|---|
| 매출 | US$29.74b |
| 매출원가 | US$6.14b |
| 총이익 | US$23.60b |
| 기타 비용 | US$14.39b |
| 순이익 | US$9.22b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 7.42 |
| 총이익률 | 79.37% |
| 순이익률 | 30.99% |
| 부채/자본 비율 | 94.6% |
GILD의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Gilead Sciences 배당 일정 | |
|---|---|
| 배당락일 | Jun 15 2026 |
| 배당 지급일 | Jun 29 2026 |
| 배당락일까지 남은 일수 | 7 days |
| 배당 지급일까지 남은 일수 | 7 days |
GILD는 안정적으로 배당을 지급합니까?
GILD 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/21 17:44 |
| 종가 | 2026/06/18 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Gilead Sciences, Inc.는 65명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |